[go: up one dir, main page]

Du, 2010 - Google Patents

The mechanisms by which CUG repeats cause myotonic dystrophy type 1

Du, 2010

Document ID
14725228260582405264
Author
Du H
Publication year

External Links

Snippet

Abstract Myotonic dystrophy type 1 (DM1) is caused by CUG expansion (CUG exp) at the 3'UTR of the dystrophia myotonica-protein kinase gene (DMPK), leading to charateristic myotonia, progressive muscle wasting and insulin resistance. To test whether MBNL1 …
Continue reading at search.proquest.com (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes
    • C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Similar Documents

Publication Publication Date Title
Li et al. Attenuation of microRNA-1 derepresses the cytoskeleton regulatory protein twinfilin-1 to provoke cardiac hypertrophy
Eom et al. NOVA-dependent regulation of cryptic NMD exons controls synaptic protein levels after seizure
Yin et al. Long noncoding RNAs with snoRNA ends
EP2691522B1 (en) Functional nucleic acid molecule and use thereof
Koebis et al. Alternative splicing of myomesin 1 gene is aberrantly regulated in myotonic dystrophy type 1
Gao et al. SR protein 9G8 modulates splicing of tau exon 10 via its proximal downstream intron, a clustering region for frontotemporal dementia mutations
Nimura et al. Regulation of alternative polyadenylation by Nkx2-5 and Xrn2 during mouse heart development
US10266828B2 (en) RAS exon 2 skipping for cancer treatment
Charton et al. Exploiting the CRISPR/Cas9 system to study alternative splicing in vivo: application to titin
US9611480B2 (en) Means and methods for counteracting, delaying and/or preventing adverse energy metabolism switches in heart disease
CA2728069C (en) Means and methods for counteracting, delaying and/or preventing heart disease
Verbeeren et al. Alternative exon definition events control the choice between nuclear retention and cytoplasmic export of U11/U12-65K mRNA
CN101466835A (en) Method for controlling the amount of gene product, and agent for controlling the amount of gene product
Du The mechanisms by which CUG repeats cause myotonic dystrophy type 1
EP2726108B1 (en) Inhibitor of neuronal connectivity linked to schizophrenia susceptibility and cognitive dysfunction
WO2020002691A1 (en) TREATMENT OF CARDIOMYOPATHY THROUGH MODULATION OF HYPOXIA-INDUCED eRNA ACTIVITY
Tomassoni-Ardori et al. Clusters of deep intronic RbFox motifs embedded in large assembly of splicing regulators sequences regulate alternative splicing
Chen et al. TGS1 controls snRNA 3’end processing, prevents neurodegeneration and ameliorates SMN-dependent neurological phenotypes in vivo
Ross et al. Inducible formation of fusion transcripts upregulates haploinsufficient CHD2 gene expression
Grinman Investigations into Hippocampal Long Noncoding RNAs in Learning-Related Signaling
CN115873935A (en) Application of Hilnc or signal path containing Hilnc as target for regulating lipid metabolism
Turner Functional Interrogation of the COL4A1/COL4A2 and SMAD3 Coronary Artery Disease Loci
Llamusí et al. Expanded CTG Repeat Induced Molecular Alterations in Myotonic Dystrophy
Havens Co-regulation of microRNA biogenesis and host gene premessenger RNA splicing in disease
Jeck An Investigation of Circular RNAs on a Genome-Wide Scale